Allogeneic iPSC-derived γδT cells demonstrate antitumor efficacy against patient-derived tissues

Area of Science:

• Oncology
• Immunotherapy
• Stem Cell Biology

Background:

• Current immunotherapies like CAR-T cell therapy show limited efficacy against solid tumors.
• Gamma delta T (γδT) cells possess potent tumor cytotoxicity and MHC-unrestricted activity, making them promising for cancer treatment.
• Induced pluripotent stem cells (iPSCs) offer a renewable source for generating immune cells.

Purpose of the Study:

• To investigate the potential of allogeneic induced pluripotent stem cell-derived gamma delta T (iγδT) cells as a novel immunotherapy for colorectal cancer.
• To evaluate the in vitro and in vivo cytotoxicity of iγδT cells against colorectal cancer models.

Main Methods:

• Generation of γδT cells from iPSCs.
• Assessment of iγδT cell cytotoxicity against colorectal cancer cell lines and patient-derived organoids in vitro.
• Evaluation of iγδT cell efficacy in vivo through local and intravenous administration in tumor models.

Main Results:

• iγδT cells demonstrated significant in vitro cytotoxicity (70%-90%) against colorectal cancer cell lines and organoids.
• In vivo administration of iγδT cells resulted in substantial tumor growth suppression (70%-100%).
• Patient-derived organoids better recapitulate tumor heterogeneity and drug sensitivity compared to cell lines.

Conclusions:

• Allogeneic iγδT cells are a promising cell-based immunotherapy for colorectal cancer.
• iγδT cells exhibit potent anti-tumor effects in both in vitro and in vivo models.
• This approach holds potential for overcoming limitations of current immunotherapies for solid tumors.